Status:
UNKNOWN
Study on Novel Peripheral Blood Diagnostic Biomarkers for MCI Due to Alzheimer's Disease
Lead Sponsor:
Shanghai Mental Health Center
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50-90 years
Brief Summary
The prevalence of Mild Cognitive Impairment (MCI) is about 15%-17%. 10%-15% of MCI progresses to Alzheimer's disease (AD) every year. The annual incidence of MCI in the normal elderly is about 1%. Per...
Eligibility Criteria
Inclusion
- 2011 NIA-AA criteria of MCI due to AD or AD or - 2017 Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium or - 2001 the McKhann consensus clinical criteria for FTD (McKhann et al.)
Exclusion
- Dementia caused by infection or substance
- Thyroid disease
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
1300 Patients enrolled
Trial Details
Trial ID
NCT04509271
Start Date
October 1 2020
End Date
September 30 2022
Last Update
September 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China, 200030